C

CVRx Inc
NASDAQ:CVRX

Watchlist Manager
CVRx Inc
NASDAQ:CVRX
Watchlist
Price: 12.9 USD 3.2%
Market Cap: 313m USD
Have any thoughts about
CVRx Inc?
Write Note

CVRx Inc
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CVRx Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
C
CVRx Inc
NASDAQ:CVRX
Free Cash Flow
-$39.6m
CAGR 3-Years
-34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Free Cash Flow
$3.1B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
11%
Boston Scientific Corp
NYSE:BSX
Free Cash Flow
$2.2B
CAGR 3-Years
12%
CAGR 5-Years
28%
CAGR 10-Years
10%
Stryker Corp
NYSE:SYK
Free Cash Flow
$3.2B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Free Cash Flow
$6.5B
CAGR 3-Years
-11%
CAGR 5-Years
11%
CAGR 10-Years
8%
Intuitive Surgical Inc
NASDAQ:ISRG
Free Cash Flow
$586m
CAGR 3-Years
-32%
CAGR 5-Years
-11%
CAGR 10-Years
-1%
No Stocks Found

CVRx Inc
Glance View

Market Cap
312.2m USD
Industry
Health Care

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.

CVRX Intrinsic Value
11.28 USD
Overvaluation 13%
Intrinsic Value
Price
C

See Also

What is CVRx Inc's Free Cash Flow?
Free Cash Flow
-39.6m USD

Based on the financial report for Dec 31, 2023, CVRx Inc's Free Cash Flow amounts to -39.6m USD.

What is CVRx Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-34%

Over the last year, the Free Cash Flow growth was 9%. The average annual Free Cash Flow growth rates for CVRx Inc have been -34% over the past three years .

Back to Top